

## Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases

Pierre Payoux, Jean-Philippe Ranjeva

### ► To cite this version:

Pierre Payoux, Jean-Philippe Ranjeva. Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases. Thérapie, 2021, 76 (2), pp.121-126. 10.1016/j.therap.2020.12.008 . hal-03500764

## HAL Id: hal-03500764 https://amu.hal.science/hal-03500764

Submitted on 24 Apr 2023  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## **THERAPIES**

## **HEADING:** Neuropsychopharmacology

# Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases.

PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases

Pierre Payoux <sup>a,\*</sup>, Jean-Philippe Ranjeva<sup>b</sup>

a ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France. Nuclear Medicine Department University Hospital of Toulouse France.
b CNRS, CRMBM, Aix-Marseille University, 13385 Marseille, France; AP-HM, University Hospital Timone, CEMEREM, 13385 Marseille, France.

Received June 15, 2020; accepted September 29, 2020

\***Corresponding author**. UMR1214 - Inserm/UPS – ToNIC Toulouse NeuroImaging Center, Pavillon Baudot, CHU Purpan, 31059 Toulouse Cedex 3, France.

*E-mail address*: payoux.p@chu-toulouse.fr (P. Payoux)

#### Abbreviations

- 11C-PIBPET: [11 C] Pittsburg compound-B
- Aβ: β amyloid
- AADC: aromatic amino acid decarboxylase
- AD: Alzheimer's disease
- APP: amyloid precursor protein
- BBB: blood brain barrier
- CNS: central nervous system
- DAT: dopamine transporter
- LBD: Lewy body disease
- MCI: mild cognitive impairment
- MRI: magnetic resonance imaging
- MSA: multiple system atrophy
- NFTs: neurofibrillary tangles
- PET: positron emission tomography
- PHF: paired helicoid filaments
- SERT: serotonine reuptake transporter
- VMAT2: vesicular monoamine transporter

#### **Summary**

This manuscript reviews the contributions of the neuroimaging methods including PET, conventional and advanced MRI methods to monitor the effect of new disease modifying drugs in neurodegenerative diseases. It now seems obvious that in many pathologies these two techniques are more and more complementary

#### **KEYWORDS**

Neuroimaging, Neurodegenerative diseases, PET, MRI, clinical trials.

#### Introduction

In the past decades positron emission tomography (PET) and magnetic resonance imaging (MRI) neuroimaging has been widely used in neurosciences to validate and follow specific treatments in central nervous system (CNS) diseases.

Those approaches have been principally used in neurodegenerative disorders such as dementia or parkinsonism, in stroke and in neuroinflammatory disease (multiple sclerosis).

The specificity of PET radiopharmaceuticals is to allow the labelling of small molecules able to cross the blood brain barrier with respect of their biological properties. The short physical period of 11C (20 minutes) limiting its use to specific centres so the tracers labelled with 18F (110 minutes half-life time) has been widely developed. Molecular imaging with PET is one of the biomarkers indispensable for pharmacological research. Currently, in neurosciences field, the treatment options for several pathologies, especially neurodegenerative diseases, remain supportive and symptomatic. Therefore, treatments allowing to slow down or reverse disease progression are the subject of numerous studies in which molecular imaging is promising. If it is well known that radiopharmaceuticals could improve the diagnosis of many neurologic diseases it is also obvious that this neuroimaging approach could be used to screening patients eligibility for potential new treatment, or for treatment follow-up.

In the other hand, the specificity of MRI is to provide high contrast between different watercontaining CNS tissues according to their relaxation times ( $T_1$ ,  $T_2$ ). Thus, high resolution-high contrasted MR images give access, not only to the depiction and progression monitoring of macroscopic lesions, but also to the evaluation of global, regional and local CNS atrophy through image segmentation procedures. Conventional MRI allows also to probe the integrity of the blood brain barrier (BBB) using injection of Gadolinium contrast media on  $T_1$ -weighted MRI. More quantitative MRI methods enable to probe CNS microstructure (diffusion and magnetization transfer MRI), CNS iron contains ( $T_2$ \*, susceptibility-weighted imaging, quantitative susceptibility mapping), metabolism (MR spectroscopic imaging), vascularization (MR angiography) and hemodynamic (perfusion MRI). Finally, functional MRI allows to study brain activation and reorganization at rest and during specific task.

To date, a vast majority of clinical trials have used MR imaging endpoints based on conventional MRI (number and volume of lesions, presence and topography of Gd enhancement, global and regional volumetry of brain structures). More specific advanced MRI methods appear very promising to probe efficacy of new drugs but suffer for difficulties to standardize acquisitions across sites and manufacturers. Several international initiatives have been launched for two decades to provide standardized protocols, database and post-processing pipeline, and still ongoing works are running to reach this goal, integrating continuously the new advances in the MR field to provide robust and fast protocols compatible with large clinical trials.

The aim of this short review is to map out major innovative PET radiotracers used in neurodegenerative diseases, and to explain their part in clinical research and in parallel explain the adds-on of MRI in the monitoring of dementia and parkinsonism.

#### **Neurodegenerative diseases**

#### Dementia

#### PET imaging

#### Amyloid gras

 $\beta$ -amyloid (A $\beta$ ) plaques in the brain are one of specific histopathologic lesions of Alzheimer's disease (AD) [1]. Progress in the understanding of the physiopathology of AD suggest that progressive amyloid accumulation begins during the presymptomatic phase, followed by synaptic dysfunction, tau-mediated neuronal injury, a reduction in brain volume, and finally the emergence of cognitive symptoms, followed by a clinical syndrome of overt dementia. This suggest that A $\beta$  imaging is a critical step for the early diagnosis of AD [2].

These deposits were first imaged in PET in 2004, using a thioflavin-T derivative: 11C-Pittsburgh compound B ([11C]-PIB) [3]. So, this "historical" compound is the best known but its use is restricted to the few research centres, owing to the short half-life of 11C. Numerous studies have showed that [11C]-PIB uptake is correlate with binds to A $\beta$  plaques cortical regions in patients with AD [3–5].

[11C]-PIB binding is linked with a reduction in cerebrospinal fluid A $\beta$ 42 [6], cerebral atrophy [7], and episodic memory impairment in apparently healthy elderly individuals and those with mild cognitive impairment (MCI) [8]. These first studies have been followed by the development of several A $\beta$  plaque tracers labelled with fluorine. To date, three radiopharmaceuticals with equivalent diagnostic performances have been authorized for imaging: 18F-florbetapir (Amyvid<sup>®</sup>), 18F-florbetaben (Neuraceq<sup>®</sup>), and 18F-flutemetamol (Vizamyl<sup>®</sup>) [8].

In PET-to-autopsy studies performed with these tracers in end-of-life populations, PET scans performed during life had 88% to 98% sensitivity and 80% to 95% specificity for detecting moderate-frequent (according to the consortium to establish a registry for Alzheimer's disease scale) [9] neuritic amyloid plaques at autopsy .These results suggest that 18F-labeled tracers have better sensitivity and specificity than clinical diagnosis and other biomarkers commonly used in practice, and are comparable to 11C-PiB. However, the extent and distribution of A $\beta$  plaques and amyloid PET tracer binding in patients are only moderately correlated with patterns of neurodegeneration and cognitive deficits. This suggests that A $\beta$  deposition, which is a hallmark for diagnosing AD, is only a biomarker of a cascade of other physiopathological events, rather than the cause of neurodegeneration and clinical disease progression [10].

In this respect, these radiopharmaceuticals are used for their very good negative predictive value. A negative scan (i.e., amyloid uptake extremely low) is considered to be incompatible with a diagnosis of AD. Although a moderate-to-high amyloid plaque density may point to AD, a positive test is not sufficient prove this disorder. So the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer's Association delineated "appropriate use criteria" in 2013, identifying three clinical circumstances in which amyloid PET imaging is recommended to precise the diagnosis: "Patients with persistent or progressive unexplained mild cognitive impairment", "Patients satisfying core clinical criteria for possible (and not probable) Alzheimer's disease (i.e., atypical clinical course or etiologically mixed presentation)", and "Patients with atypically young-onset dementia" [11].

In spite of those results, the use of amyloid PET imaging in clinical practice is still limited especially with the lack of reimbursement in many countries and, in France, the absence of inclusion on the list of pharmaceutical specialties approved for use by communities.

Since the development of those compounds, amyloid PET has been widely used in clinical trials. As it is well known the treatment options for AD are unfortunately limited to symptomatic drugs, with no influence of the ultimate prognosis [12]. Numerous studies have been conducted to

find new treatments, as well as to better understand the physiopathology of AD. One of the research approaches to develop new treatments involves targeting the two pathological features of AD: senile plaques (A $\beta$ ) and neurofibrillary tangles (NFTs) e.g. aggregates of hyperphosphorylated tau protein in paired helicoid filaments (PHF). According to the amyloid cascade hypothesis, toxic plaques are supposed to be the earliest manifestation of the disease, as demonstrated by evidence of A $\beta$  up to 20 years prior to the onset of symptoms [12]. The main classes of medication under development are monoclonal anti-amyloid antibodies, and inhibitors of pathogenic cleavage of the amyloid precursor protein (APP). PET amyloid tracers in clinical trials evaluating the therapeutic potential of these medications are now used for selecting and including patients with significant A $\beta$ , or monitoring disease progression under treatment [13]. Furthermore, such neuroimaging PET studies is a good way to optimize the dose for treatment as it was demonstrated for example recently in an exploratory study with gantenerumab [14].

#### TAU imaging

One of important lack of  $A\beta$  imaging is the impossibility to follow the evolution of the disease and a low correlation with glucose hypometabolism, disease severity, progression, and clinical cognitive assessment. Clinical trials assessing monoclonal anti-amyloid antibodies have mostly failed to show a significant clinical benefit in AD. The other main histopathological figure of AD, abnormal tau protein aggregates, has therefore be considered with much interest. As so, consider PET radiopharmaceuticals targeting abnormal tau protein conformations as an alternative. Whereas,  $A\beta$ levels reach a steady state at prodromal clinical stage, the presence and extent of NFTs and neuronal injury levels are correlated with disease duration and severity of symptoms [15]. Moreover, tau has been found to be more closely related to clinical features [16]. Abnormal aggregation of tau protein has also been observed in the pathophysiology of other neurodegenerative diseases such as frontotemporal dementia, corticobasal syndrome, progressive supranuclear palsy and Lewy body disease (LBD); the abnormal conformation of tau in these diseases are distinct from that observed in AD. These tauopathies differ by the isomeric form and ultrastructural morphology of aggregated tau, affected brain regions, and spatial patterns of tau accumulation [17].

Over the past few years, several tau imaging agents have been developed: [11C]-PBB3, [18F]-AV-1451 (or flortaucipir), [18F]-T808, and the THK family [18F]-THK523, [18F]-THK5105, and [18F]-THK5351. The well-known of the first radiotracers developed for tau imaging was [18F]-FDDNP. In a recent study, an anti-tau drug exhibited a good safety profile and even

stimulated a positive immune response in human patients [18]. Several other early-phase trials of drugs that target tau protein are currently underway, although the results are yet to be published [19].

In this context, like amyloid tracers, tau radioligands have an important role to play in clinical studies assessing new treatments and measuring disease progression [20].

#### MRI imaging

For Alzheimer disease, patterns of cortical atrophy have been shown to accurately track disease progression [21]. Thus, MRI criteria in clinical trials are those related to the quantification of global and regional brain atrophy. The most common primary outcomes are the annualized percent change of total brain volume, annualized percent change of hippocampal volume, and annualized percent change of ventricular volume [22]. These parameters, first derived from manual segmentation are now obtained using semi-automatic [23] or automatic segmentation [24, 25] of high resolution (typically 1mm3 voxel size) volumic T1-weighted acquisitions, relatively easily standardized across sites.

Regional and voxel based atrophy maps were shown to be sensitive and specific enough to observe the progression of disease even in prodromal AD [26], and to distinguish between AD subtypes [27].

More precise automatic delineation of specific regions of interest such as the hippocampal or amygdalar subfields should contribute to improve monitoring of disease progression [28]. Concurrently, the development of ultra-high field MR scanner (7T and more) brings new perspectives to improve spatial resolution and signal to noise ratio of MRI, leading to the depiction of laminar abnormalities in hippocampal subfields , and improved sensitivity to magnetic susceptibility of b-amyloid aggregates [29] and iron accumulation reflecting neurodegeneration [30]. Standardization of protocols are ungoing in the UHF community to provide tools to construct large common database on neurodegenerative diseases [31].

But to date, no real efficacy of treatments in AD have been really observed [22]. One of the potential reasons, letting apart low effects of drugs on neurodegeneration, could be the difficulty to stratify groups of AD patients for inclusion in clinical trials. In this field, MRI could also help in the definition of more homogenous groups of patients through assessment of comorbid vascular pathologies using quantification of  $T_2$  white matter hyperintensities [32].

In addition, combination of multimodal biomarkers derived from EEG, conventional MRI and resting state fMRI appear promising to track more sensitively subtle longitudinal changes related to disease progression even in the prodromal stage of AD [33, 34].

#### Parkinsonism

Today, the dopaminergic pathways is widely explored [22] by PET or SPECT radiopharmaceuticals and contribute to the diagnosis of Parkinson's disease (PD), other Parkinsonian syndromes, and LBD [35].

Historically The first radiotracer to be introduced for the non-invasive assessment of nigrostriatal terminals was [18F]-DOPA in 1983 [23]. This radiotracer reflects the enzymatic activity of aromatic amino acid decarboxylase (AADC), and conversion of L-DOPA to dopamine, through its subsequent accumulation in the dopamine neurons. Striatal F-DOPA uptake has been found to be closely related to the nigral cell count, except at the beginning of the disease as a consequence of functional compensation (F-DOPA uptake is preserved while motor symptoms can be already presents) [36]. This molecule has a history of more than 30 years in clinical research and for the diagnosis of PD. However, in the past decade, the clinical practice led to prefer structural targets such as membrane dopamine transporter (DAT). Those compounds have an high sensitivity for detecting presynaptic dopaminergic degeneration at early-stage of PD. F-DOPA has recently regained interest in the context of regenerative therapy for PD such as the implantation of dopaminergic cells or the infusion of drugs with regenerating effects for striatal cells [37]. The purpose of this therapy is to regenerate the dopaminergic presynaptic function by converting L-DOPA to dopamine. In that cases, DAT tracers are considered to be less relevant for measuring therapeutic response than F-DOPA.

DAT ligands target dopamine transporters located on dopaminergic nerve cell terminals. In contrast to the AADC, the DAT are only localized on dopamine neurons. However, the ligands used for its imaging may also bind to other transporters, such as the serotonine reuptake transporter (SERT) or the norepinephrine reuptake transporter [10]. Today in clinical routine, most of DAT tracers are developed for SPECT imaging. Due to the higher spatial resolution and better sensitivity of PET, some new radiopharmaceuticals labelled with fluorine has been developed recently.

Thus, based on the properties of PE2I a new DAT tracer LBT-999, exploited by Zionexa has been developed, which could be used in future PET explorations using fluorine-18 [38]. Because of its higher resolution, PET imaging is more useful than SPECT for accurate in vivo quantification of DAT density. LBT-999 is a phenyltropane derivative that has demonstrated its suitability for in vivo quantification of DAT in non-human primates [29]. An in vivo kinetic study in baboons confirmed that LBT-999 brain uptake is fast, high, and mainly located in the putamen and caudate, with peak uptake in these regions at 30 min postinjection instead of 3 to 4 hours for PET ligands. A third way of investigating the function of dopamine terminals is to measure the density of vesicular monoamine transporter (VMAT2), which is responsible for taking up neurotransmitters into presynaptic secretory vesicles. Although a majority of VMAT2 are expressed in dopaminergic terminals, this transporter is also located in various monoaminergic neurons, and is involved in the vesicular trapping of a wide variety of neurotransmitters including dopamine, serotonin, norepinephrine, and epinephrine. This target can be investigated with [11C]-DTBZ, or more recently with fluorinated analog [18F]-AV-133, by PET [30]. This presynaptic marker follows very typical patterns in several neurodegenerative diseases affecting dopaminergic function, such as PD, LBD, multiple system atrophy (MSA), PSP, and CBS. Their uptake/binding are altered in several brain areas, depending on the disease and its stage [31]. In contrast to AADC activity or DAT binding, it has been suggested that VMAT2 activity is less inclined to changes induced by medication or compensatory mechanisms. However, VMAT2 activity can be impacted by the density of vesicular dopamine, competing at the recognition site. Hence, the level of VMAT2 binding may decrease with levodopa administration [32]. These tracers have a future in early detection/screening, diagnosis, and neuroprotective treatment follow-up of these neurodegenerative diseases, as well as in the monitoring of neural grafted cells after transplantation [8].

In the other hand, dopaminergic neurotransmission can also be focused on postsynaptic D2 receptors with [11C]-raclopride and [18F]-fallypride [8, 31]. The concomitant study of DAT and D2 receptors may improve the diagnostic value of molecular imaging in differentiating between PD and other parkinsonian syndromes [33, 34]. In PD, at the beginning of the disease the lesions are only presents on the pre synaptic size to the difference of PSP or MAS. Molecular imaging of dopamine D2 receptors has also been used to study dopamine's role in drug abuse and addiction [36], and to evaluate several neuropsychiatric disorders [37].

MRI

Concurrently to nuclear medicine imaging which provides the extent of cellular, metabolic and synaptic dysfunction, MRI is used in Parkinson related disease for differential diagnosis [39], with development of automatic machine learning approaches [40].

The brain imaging working group of the JPNP has proposed a frameworks of neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders [41]. In combination with Tau PET, probing dysregulation of cellular processes, FDG PET, probing metabolism abnormalities, and DAT SPECT probing synaptic dysfunction, volumetric MRI should contribute to characterize the extent of structural disintegration of specific regions or networks [42], resting state fMRI can probe functional network dysfunction [43] while task-related fMRI helps to evaluate the extent of brain reorganization and even the functional effect of exercice on cognitive systems (EXPAND trial) [44].

Neuronal loss within the dopaminergic system can also be estimated by MRI contrasts sensitive to the paramagnetic properties of neuromelanine. Promising advances using ultra high field MR scanners with high resolution T1-w MRI or susceptibility weighted MRI (T2\*, SWI or QSM) aim at characterizing the neuronal loss in crucial – but small- structures such as the locus coeruleus, early involved in most of neurodegenerative diseases [45]. QSM and SWI are also useful to evaluate brain iron deposition that appear linked with cognitive impairment in Parkinson patients [46].

Multimodal and multiparametric imaging and functional index are developed and improved to provide prognostic factor of disease progression in PD and PSP [42,47,48].

#### Conclusion

There is a need for biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. In that way, PET and MRI appears to be complementary tools and can be obtained in a single scan with hybrid PET-MRI scanners.

**Disclosure of interest** Authors have no competing interest to declare **Acknowledgments**  Thanks to Dr Anne Sophie Salabert and Dr Marie Beaurain for their precious help. The work has been supported in part by a grant from the French National Agency for Research called Investissements d'Avenir (ANR-11-LABX-0018-01).

#### References

[1] Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography  $\beta$ -amyloid plaque imaging agents. Semin Nucl Med 2012;42(6):423-32.

[2] Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc 2018;14(4):535-62.

[3] Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306-19.

[4] Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64(3):431-4.

[5] Hatashita S, Yamasaki H. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 2010;21(3):995-1003.

[6] Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59(3):512-9.

[7] Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67(3):317-24.

[8] Payoux P, Salabert AS. New PET markers for the diagnosis of dementia. Curr Opin Neurol 2017;30(6):608-16.

[9] Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8(1):1-13.

[10] Laforce R, Soucy JP, Sellami L, Dallaire-Théroux C, Brunet F, Bergeron D, et al. Molecular imaging in dementia: Past, present, and future. Alzheimers Dement 2018;14(11):1522-52.

[11] Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013;9(1):e-1-16.

[12] Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment.F1000Research 2018;7:F1000 Faculty Rev-1161. doi: 10.12688/f1000research.14506.1.

[13] Delrieu J, Ousset PJ, Voisin T, Vellas B. Amyloid beta peptide immunotherapy in Alzheimer disease. Rev Neurol (Paris) 2014;170(12):739-48.

[14] Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, et al. Gantenerumab reduces amyloid- $\beta$  plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther 2019;11(1):101.

[15] Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41(1):17-24.

[16] Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegener 2017;12(1):19.

[17] Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O'Brien JT. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev 2017;36:50-63.

[18] Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 2017;16(2):123-34.

[19] Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, et al. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. Immunotherapy 2016;8(9):1119-34.

[20] Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatry 2019;24(8):1112-34.

[21] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid  $\beta$  deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12(4):357-67.

[22] Kishi T, Matsunaga S, Oya K, Ikuta T, Iwata N. Protection against brain atrophy by antidementia medication in mild cognitive impairment and Alzheimer's disease: meta-analysis of longitudinal randomized placebo-controlled Trials. Int J Neuropsychopharmacol 2015;18(12):pyv070.

[23] Barnes J, Scahill RI, Boyes RG, Frost C, Lewis EB, Rossor CL, et al. Differentiating AD from aging using semiautomated measurement of hippocampal atrophy rates. Neuroimage 2004;23(2):574-81.

[24] Nestor SM, Gibson E, Gao FQ, Kiss A, Black SE. A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer's disease. Neuroimage 2013;66:50-70.

[25] Bartel F, Vrenken H, Bijma F, Barkhof F, van Herk M, de Munck JC. Regional analysis of volumes and reproducibilities of automatic and manual hippocampal segmentations. Plos One 2017;12(2):e0166785.

[26] The PharmaCog Consortium, Marizzoni M, Ferrari C, Jovicich J, Albani D, Babiloni C, et al. Predicting and tracking short term disease progression in amnestic mild cognitive impairment patients with prodromal Alzheimer's disease: structural brain biomarkers. J Alzheimers Dis 2019;69(1):3-14.

[27] Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain atrophy in Alzheimer's Disease and aging. Ageing Res Rev 2016;30:25-48.

[28] Quattrini G, Pievani M, Jovicich J, Aiello M, Bargalló N, Barkhof F, et al. Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. Neuroimage 2020;218:116932.

[29] Tiepolt S, Schäfer A, Rullmann M, Roggenhofer E, Netherlands Brain Bank, Gertz HJ, et al. Quantitative susceptibility mapping of amyloid- $\beta$  aggregates in Alzheimer's disease with 7T MR. J Alzheimers Dis 2018;64(2):393-404.

[30] Bulk M, Abdelmoula WM, Nabuurs RJA, van der Graaf LM, Mulders CWH, Mulder AA, et al. Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early- and late-onset Alzheimer's disease. Neurobiol Aging 2018;62:231-42.

[31] Düzel E, Acosta-Cabronero J, Berron D, Biessels GJ, Björkman-Burtscher I, Bottlaender M, et al. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). Alzheimers Dement (Amst) 2019;11:538-49.

[32] ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, et al. Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimers Res Ther 2018;10(1):112.

[33] van Rooden S, van den Berg-Huysmans AA, Croll PH, Labadie G, Hayes JM, Viviano R, et al. Subjective cognitive decline is associated with greater white matter hyperintensity volume. J Alzheimers Dis 2018;66(3):1283-94.

[34] Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, et al. Biomarker matrix to track short term disease progression in amnestic mild cognitive impairment patients with prodromal Alzheimer's disease. J Alzheimers Dis 2019;69(1):49-58.

[35] de Natale ER, Niccolini F, Wilson H, Politis M. Molecular imaging of the dopaminergic system in idiopathic Parkinson's disease. Int Rev Neurobiol 2018;141:131-72.

[36] Ribeiro MJ, Remy P, Bendriem B, Almeida P, Brulon V, Samson Y, et al. Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa. Eur J Nucl Med 2000;27(6):707-12.

[37] Akamatsu G, Ohnishi A, Aita K, Nishida H, Ikari Y, Sasaki M, et al. A revisit to quantitative PET with 18F-FDOPA of high specific activity using a high-resolution condition in view of application to regenerative therapy. Ann Nucl Med 2017;31(2):163-71.

[38] Chalon S, Vercouillie J, Payoux P, Deloye JB, Malherbe C, Le Jeune F, et al. The story of the dopamine transporter PET tracer LBT-999: from conception to clinical use. Front Med (Lausanne) 2019;6:90.

[39] Berman SB, Miller-Patterson C. PD and DLB: brain imaging in Parkinson's disease and dementia with Lewy bodies. Prog Mol Biol Transl Sci 2019;165:167-85.

[40] Archer DB, Bricker JT, Chu WT, Burciu RG, McCracken JL, Lai S, et al. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health 2019;1(5):e222-31.

[41] van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a neuroimaging biomarker utility system. Alzheimers Dement (Amst) 2019;11:301-9.

[42] Zeighami Y, Fereshtehnejad SM, Dadar M, Collins DL, Postuma RB, Dagher A. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease. Neuroimage Clin 2019;24:101986.

[43] Tessitore A, Cirillo M, De Micco R. Functional connectivity signatures of Parkinson's disease.J Parkinsons Dis 2019;9(4):637-52.

[44] Franzén E, Johansson H, Freidle M, Ekman U, Wallén MB, Schalling E, et al. The EXPANd trial: effects of exercise and exploring neuroplastic changes in people with Parkinson's disease: a study protocol for a double-blinded randomized controlled trial. BMC Neurol 2019;19(1):280.

[45] Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero J, Callaghan MF, et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain 2019;142(9):2558-71.

[46] Thomas GEC, Leyland LA, Schrag AE, Lees AJ, Acosta-Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson's disease. J Neurol Neurosurg Psychiatry avr 2020;91(4):418-25.

[47] Nigro S, Arabia G, Antonini A, Weis L, Marcante A, Tessitore A, et al. Magnetic resonance parkinsonism index: diagnostic accuracy of a fully automated algorithm in comparison with the

manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. Eur Radiol 2017;27(6):2665-75.

[48] Quattrone A, Morelli M, Quattrone A, Vescio B, Nigro S, Arabia G, et al. Magnetic resonance parkinsonism index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study. Parkinsonism Relat Disord 2020;72:1-6.